Adiponectin predicts MMP-2 activity independently of obesity

European Journal of Clinical Investigation

Volumn 44, Issue 10, 2014, Pages 951-957

  Miksztowicz, Verónica ^a,b   Fernandez Machulsky, Nahuel ^a   Lucero, Diego ^a   Fassio, Eduardo ^c   Schreier, Laura ^a   Berg, Gabriela ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Consejo Nacional de Investigaciones Científicas y Técnicas ^*  (Argentina)

^c HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

Author keywords

Adiponectin; MMP 2; Obesity

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GELATINASE A; LIPOPROTEIN;

ADULT; AGED; CASE CONTROL STUDY; ENZYMOLOGY; FEMALE; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; OBESITY; PHYSIOLOGY; YOUNG ADULT;

ADIPONECTIN; ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEINS; MALE; MATRIX METALLOPROTEINASE 2; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; YOUNG ADULT;

EID: 84908667711     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12328     Document Type: Article

References (30)

1. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73.
2. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerosis lesions. Am J Pathol 1996;148:121-8.
3. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
4. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009;58:718e25.
5. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008;37:635-46.
6. Miksztowicz V, Muzzio ML, Royer M, Prada M, Wikinski R, Schreier L et al. Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome. Metabolism 2008;57:1493-6.
7. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005;25:391-406.
8. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
9. Haffner SM, Cassells HB. Metabolic syndrome-a new risk factor of coronary heart disease? Diabetes Obes Metab 2003;5:359-70.
10. Ohash K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectina. Biochimie 2012;94:2137-42.
11. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009;73:608-14.
12. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046-9.
13. Berg G, Miksztowicz V, Schreier L. Metalloproteinases in metabolic syndrome. Clin Chim Acta 2011;412:1731-9.
14. Cimmino G, Ragni M, Cirillo P, Petrillo G, Loffredo F, Chiariello M et al. C-reactive protein induces expression of matrix metalloproteinase-9: a possible link between inflammation and plaque rupture. Int J Cardiol 2013;168:981-6.
15. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III). JAMA 2001;285:2486-97.
16. Muzzio ML, Miksztowicz V, Brites F, Aguilar D, Repetto EM, Wikinski R et al. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res 2009;40:48-53.
17. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 2007;5:265-82.
18. Gonçalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009;403:173-7.
19. Aquilante CL, Beitelshees AL, Zineh I. Correlates of serum matrix metalloproteinase- 8 (MMP-8) concentrations in non-diabetic subjects without cardiovascular disease. Clin Chim Acta 2007;379:48-52.
20. Villarreal-Molina MT, Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie 2012;94:2143-9.
21. Tong KM, Chen CP, Huang KC, Shieh DC, Cheng HC, Tzeng CY et al. Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. J Cell Biochem 2011;112:1431-40.
22. Wu X, Yan Q, Zhang Z, Du G, Wan X. Acrp30 inhibits leptin induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells. Oncol Rep 2012;27:1488-96.
23. Derosa G, Maffioli P, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med 2009;32:E124-32.
24. Bonneau GA, Pedrozo WR, Berg G. Adiponectin and waist circumference as predictors of insulin-resistance in women. Diabetes Metab Syndr 2014;8:3-7.
25. Miksztowicz V, Siseles N, Fernandez Machulsky N, Schreier L, Berg G. Increase in MMP-2 activity in overweight and obese women is associated with menopausal status. Climacteric 2012;15:602-6.
26. Gummesson A, Hagg D, Olson FJ, Hulthe J, Carlsson LM, Fagerberg B. Adipose tissue is not an important source for matrix metalloproteinase-9 in the circulation. Scand J Clin Lab Invest 2009;69:636-42.
27. Miksztowicz V, Morales C, Zago V, Friedman S, Schreier L, Berg G. Effect of insulin-resistance on circulating and adipose tissue MMP-2 and MMP-9 activity in rats fed a sucrose-rich diet. Nut Metab Cardiovas Dis 2014;24:294-300.
28. Schram K1, De Girolamo S, Madani S, Munoz D, Thong F, Sweeney G. Leptin regulates MMP-2, TIMP-1 and collagen synthesis via p38 MAPK in HL-1 murine cardiomyocytes. Cell Mol Biol Lett 2010;15:551-63.
29. Lucero D, Zago V, López GI, Graffigna M, Fainboim H, Miksztowicz V et al. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. Clin Chim Acta 2011;412:143-7.
30. Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005;54:795-802.